Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
1,052
archived clinical trials in
Nephrology

Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated:  3/16/2018
Metrolina Nephrology Associates, PA
mi
from
Charlotte, NC
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated: 3/16/2018
Metrolina Nephrology Associates, PA
mi
from
Charlotte, NC
Click here to add this to my saved trials
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated:  3/16/2018
Akron Nephrology Associates
mi
from
Akron, OH
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated: 3/16/2018
Akron Nephrology Associates
mi
from
Akron, OH
Click here to add this to my saved trials
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated:  3/16/2018
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated: 3/16/2018
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated:  3/16/2018
Nationwide Children's Hospital
mi
from
Columbus, OH
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated: 3/16/2018
Nationwide Children's Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated:  3/16/2018
Unversity of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated: 3/16/2018
Unversity of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated:  3/16/2018
Northeast Clinical Research Center, LLC
mi
from
Bethlehem, PA
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated: 3/16/2018
Northeast Clinical Research Center, LLC
mi
from
Bethlehem, PA
Click here to add this to my saved trials
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated:  3/16/2018
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated: 3/16/2018
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated:  3/16/2018
Univ of Pennsylvania
mi
from
Philadelphia, PA
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated: 3/16/2018
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated:  3/16/2018
Temple University School of Medicine
mi
from
Philadelphia, PA
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated: 3/16/2018
Temple University School of Medicine
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated:  3/16/2018
Le Bonheur Children's Hospital
mi
from
Memphis, TN
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated: 3/16/2018
Le Bonheur Children's Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated:  3/16/2018
Vanderbilt University Medical Center
mi
from
Nashville, TN
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated: 3/16/2018
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated:  3/16/2018
Clinical Advancement Center, PLLC
mi
from
San Antonio, TX
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated: 3/16/2018
Clinical Advancement Center, PLLC
mi
from
San Antonio, TX
Click here to add this to my saved trials
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated:  3/16/2018
Utah Kidney Research Center
mi
from
Salt Lake City, UT
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated: 3/16/2018
Utah Kidney Research Center
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated:  3/16/2018
Univ of Washington
mi
from
Seattle, WA
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated: 3/16/2018
Univ of Washington
mi
from
Seattle, WA
Click here to add this to my saved trials
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated:  3/16/2018
Catholic Health Initiatives Franciscan
mi
from
Tacoma, WA
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated: 3/16/2018
Catholic Health Initiatives Franciscan
mi
from
Tacoma, WA
Click here to add this to my saved trials
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated:  3/16/2018
Marshfield Clinic Research Foundation
mi
from
Marshfield, WI
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated: 3/16/2018
Marshfield Clinic Research Foundation
mi
from
Marshfield, WI
Click here to add this to my saved trials
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated:  3/16/2018
UZ Leuven
mi
from
Leuven,
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated: 3/16/2018
UZ Leuven
mi
from
Leuven,
Click here to add this to my saved trials
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated:  3/16/2018
Henry Ford Hospital
mi
from
Detroit, MI
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated: 3/16/2018
Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated:  3/16/2018
Southern Utah Kidney and Hypertension Center
mi
from
Saint George, UT
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study
Status: Enrolling
Updated: 3/16/2018
Southern Utah Kidney and Hypertension Center
mi
from
Saint George, UT
Click here to add this to my saved trials
Multi-center Controlled Clinical Trials in Alport Syndrome-A Feasibility Study
Multi-center Controlled Clinical Trials in Alport Syndrome-A Feasibility Study
Status: Enrolling
Updated:  3/21/2018
Univ of Minnesota
mi
from
Minneapolis, MN
Multi-center Controlled Clinical Trials in Alport Syndrome-A Feasibility Study
Multi-center Controlled Clinical Trials in Alport Syndrome-A Feasibility Study
Status: Enrolling
Updated: 3/21/2018
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated:  4/2/2018
Mallinckrodt Investigational Site
mi
from
Sacramento, CA
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated: 4/2/2018
Mallinckrodt Investigational Site
mi
from
Sacramento, CA
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated:  4/2/2018
Mallinckrodt Investigational Site
mi
from
Stanford, CA
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated: 4/2/2018
Mallinckrodt Investigational Site
mi
from
Stanford, CA
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated:  4/2/2018
Mallinckrodt Investigational Site
mi
from
Jacksonville, FL
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated: 4/2/2018
Mallinckrodt Investigational Site
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated:  4/2/2018
Mallinckrodt Investigational Site
mi
from
Atlanta, GA
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated: 4/2/2018
Mallinckrodt Investigational Site
mi
from
Atlanta, GA
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated:  4/2/2018
Mallinckrodt Investigational Site
mi
from
Rochester, MN
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated: 4/2/2018
Mallinckrodt Investigational Site
mi
from
Rochester, MN
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated:  4/2/2018
Mallinckrodt Investigational Site
mi
from
Reno, NV
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated: 4/2/2018
Mallinckrodt Investigational Site
mi
from
Reno, NV
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated:  4/2/2018
Mallinckrodt Investigational Site
mi
from
New York, NY
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated: 4/2/2018
Mallinckrodt Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated:  4/2/2018
Mallinckrodt Investigational Site
mi
from
Chapel Hill, NC
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated: 4/2/2018
Mallinckrodt Investigational Site
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated:  4/2/2018
Mallinckrodt Investigational Site
mi
from
Durham, NC
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated: 4/2/2018
Mallinckrodt Investigational Site
mi
from
Durham, NC
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated:  4/2/2018
Mallinckrodt Investigational Site
mi
from
Bethlehem, PA
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated: 4/2/2018
Mallinckrodt Investigational Site
mi
from
Bethlehem, PA
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated:  4/2/2018
Mallinckrodt Investigational Site
mi
from
Charleston, SC
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated: 4/2/2018
Mallinckrodt Investigational Site
mi
from
Charleston, SC
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated:  4/2/2018
Mallinckrodt Investigational Site
mi
from
Chattanooga, TN
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated: 4/2/2018
Mallinckrodt Investigational Site
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated:  4/2/2018
Mallinckrodt Investigational Site
mi
from
Houston, TX
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated: 4/2/2018
Mallinckrodt Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated:  4/2/2018
Mallinckrodt Investigational Site
mi
from
Lubbock, TX
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated: 4/2/2018
Mallinckrodt Investigational Site
mi
from
Lubbock, TX
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated:  4/2/2018
Mallinckrodt Investigational Site
mi
from
Toronto,
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated: 4/2/2018
Mallinckrodt Investigational Site
mi
from
Toronto,
Click here to add this to my saved trials
Evaluation of Albuminuria HIV-Infected Patients
Prospective Evaluation of Albuminuria in HIV Positive Patients
Status: Enrolling
Updated:  4/4/2018
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Evaluation of Albuminuria HIV-Infected Patients
Prospective Evaluation of Albuminuria in HIV Positive Patients
Status: Enrolling
Updated: 4/4/2018
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Evaluation of Albuminuria HIV-Infected Patients
Prospective Evaluation of Albuminuria in HIV Positive Patients
Status: Enrolling
Updated:  4/4/2018
MedStar Washington Hospital Center
mi
from
Washington,
Evaluation of Albuminuria HIV-Infected Patients
Prospective Evaluation of Albuminuria in HIV Positive Patients
Status: Enrolling
Updated: 4/4/2018
MedStar Washington Hospital Center
mi
from
Washington,
Click here to add this to my saved trials
Effect of Increasing Doses of Cystine Binding Thiol Drugs on Cystine Capacity in Patients With Cystinuria
Effect of Increasing Doses of Cystine Binding Thiol Drugs on Cystine Capacity in Patients With Cystinuria
Status: Enrolling
Updated:  4/4/2018
NYU Langone Medical Center
mi
from
New York, NY
Effect of Increasing Doses of Cystine Binding Thiol Drugs on Cystine Capacity in Patients With Cystinuria
Effect of Increasing Doses of Cystine Binding Thiol Drugs on Cystine Capacity in Patients With Cystinuria
Status: Enrolling
Updated: 4/4/2018
NYU Langone Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Indwelling Double-J Ureteral Stent Versus Externalized Modified-Salle Stent for Pyeloplasty
Prospective Randomized Trial of Indwelling Double-J Ureteral Stent Versus Externalized Modified-Salle Stent for Pyeloplasty
Status: Enrolling
Updated:  4/9/2018
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Indwelling Double-J Ureteral Stent Versus Externalized Modified-Salle Stent for Pyeloplasty
Prospective Randomized Trial of Indwelling Double-J Ureteral Stent Versus Externalized Modified-Salle Stent for Pyeloplasty
Status: Enrolling
Updated: 4/9/2018
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
The Effects of Vitamin D Repletion in Vitamin D Deficient Patients With Stage 3 and 4 Chronic Kidney Disease
The Effects of Vitamin D Repletion in Vitamin D Deficient Patients With Stage 3 and 4 Chronic Kidney Disease
Status: Enrolling
Updated:  4/19/2018
Montefiore Medical Center
mi
from
Bronx, NY
The Effects of Vitamin D Repletion in Vitamin D Deficient Patients With Stage 3 and 4 Chronic Kidney Disease
The Effects of Vitamin D Repletion in Vitamin D Deficient Patients With Stage 3 and 4 Chronic Kidney Disease
Status: Enrolling
Updated: 4/19/2018
Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Multi-center, Retrospective Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Status: Enrolling
Updated:  4/30/2018
Clinical Research Facility
mi
from
Chicago, IL
Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Multi-center, Retrospective Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Status: Enrolling
Updated: 4/30/2018
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Multi-center, Retrospective Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Status: Enrolling
Updated:  4/30/2018
Clinical Research Facility
mi
from
Evanston, IL
Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Multi-center, Retrospective Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Status: Enrolling
Updated: 4/30/2018
Clinical Research Facility
mi
from
Evanston, IL
Click here to add this to my saved trials
Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Multi-center, Retrospective Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Status: Enrolling
Updated:  4/30/2018
Clinical Research Facility
mi
from
Detroit, MI
Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Multi-center, Retrospective Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Status: Enrolling
Updated: 4/30/2018
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Multi-center, Retrospective Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Status: Enrolling
Updated:  4/30/2018
Clinical Research Facility
mi
from
New Brunswick, NJ
Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Multi-center, Retrospective Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Status: Enrolling
Updated: 4/30/2018
Clinical Research Facility
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Multi-center, Retrospective Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Status: Enrolling
Updated:  4/30/2018
Clinical Research Facility
mi
from
Somers Point, NJ
Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Multi-center, Retrospective Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Status: Enrolling
Updated: 4/30/2018
Clinical Research Facility
mi
from
Somers Point, NJ
Click here to add this to my saved trials
Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Multi-center, Retrospective Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Status: Enrolling
Updated:  4/30/2018
Clinical Research Facility
mi
from
New York, NY
Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Multi-center, Retrospective Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Status: Enrolling
Updated: 4/30/2018
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Multi-center, Retrospective Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Status: Enrolling
Updated:  4/30/2018
Clinical Research Facility
mi
from
Rochester, NY
Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Multi-center, Retrospective Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Status: Enrolling
Updated: 4/30/2018
Clinical Research Facility
mi
from
Rochester, NY
Click here to add this to my saved trials
Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Multi-center, Retrospective Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Status: Enrolling
Updated:  4/30/2018
Clinical Research Facility
mi
from
Durham, NC
Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Multi-center, Retrospective Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Status: Enrolling
Updated: 4/30/2018
Clinical Research Facility
mi
from
Durham, NC
Click here to add this to my saved trials
Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Multi-center, Retrospective Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Status: Enrolling
Updated:  4/30/2018
Clinical Research Facility
mi
from
Cleveland, OH
Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Multi-center, Retrospective Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Status: Enrolling
Updated: 4/30/2018
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Multi-center, Retrospective Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Status: Enrolling
Updated:  4/30/2018
Clinical Research Facility
mi
from
Pittsburgh, PA
Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Multi-center, Retrospective Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
Status: Enrolling
Updated: 4/30/2018
Clinical Research Facility
mi
from
Pittsburgh, PA
Click here to add this to my saved trials